scholarly journals Intensity of systemic proteolysis and endotoxicosis in patients with non-alcoholic steatohepatitis associated with obesity and comorbid chronic obstructive pulmonary disease in the dynamics of treatment with hepatoprotectors

2020 ◽  
Vol 54 (2) ◽  
pp. 101-106
Author(s):  
O.S. Khukhlina ◽  
O.Ye. Hrinyuk ◽  
O.D. Liakhovych
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Steatohepatitis

scholarly journals PATHOMORPHOLOGY OF FIBROSING PROCESSES IN THE LIVER AND LUNGS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS AND OBESITY AT COMORBIDITY WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
O.Ye. Hryniuk ◽  
I.S. Davydenko ◽  
O.S. Khukhlina ◽  
A.A. Antoniv ◽  
V.S. Haidychuk
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Connective Tissue ◽  
Pulmonary Disease ◽  
Optical Density ◽  
Specific Volume ◽  
Liver Parenchyma ◽  
Collagen Fibers ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Steatohepatitis

Objective - to study the histochemical and histological features of the liver and lungtissues in patients with non-alcoholic steatohepatitis (NASH) and obesity under conditionof a comorbid course with chronic obstructive pulmonary disease (COPD).Material and methods. The autopsy material of 27 cases with NASH, including 13 casesof NASH and obesity of I degree (group 1), 14 cases of NASH, obesity of I degree withcomorbid COPD of II-III stage (group 2) was used. The groups of comparison includedautopsy material of 12 patients with isolated COPD of II-III stage (Group 3), as wellas 11 practically healthy persons (PHP), their main causes of death were polytraumaor traumatic brain injury or sudden coronary death. The groups were randomizedaccording to age, sex, degree of obesity. The average age of patients was (59,3 ± 3,21)years.Results. The volume of the connective tissue (CT) in the liver parenchyma in the 2nd groupwas in 1,9 times higher than in the 1st group (p<0,05), the specific volume of collagenfibers in 1,4 times, the optical density of collagen fibers by 1,2 times (p<0,05). In the 2ndgroup, the maximum damage to the respiratory parts of the lungs (RPL) was establishedin terms of percentage of filling of the RPL spaces with desquamated cells (in 9.4 times incomparison with PHP, by 1,3 times compared to the indicator in the 3rd group); specificvolume growth of the blood vessels in the peribronchial CT by 1,4 times (p<0,05). Thephenomena of venous thrombosis are most pronounced both in the peribronchial CT(they exceed the indicator in the 3rd group by 1,2 times) and respiratory parts of the lungs(by 2,4 times) (p<0,05). Patients of the 2nd group had the highest values of the specificvolume of CT in the lungs among all groups under study (19,8 ± 0,37 (p <0,05)).Conclusions. The comorbidity of COPD in patients with NASH and obesity contributedto the higher degree of activation of the connective tissue components in the liverparenchyma in comparison with the NASH indicators against a background of obesitywithout COPD, with an increase in the volume of the connective tissue (in 1,9 times,p<0,05), specific volume collagen fibers (by 1,4 times, p<0,05), optical density ofcollagen fibers coloring (in 1,2 times, p<0,05).

Clinical efficacy of hepatoprotector in the complex therapy of non-alcoholic steatohepatitis against the background of obesity for comorbidity with chronic obstructive pulmonary disease

2021 ◽  
Author(s):  
O. S. Khukhlina ◽  
O. Ye. Hryniuk
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Liver Steatosis ◽  
Subjective Assessment ◽  
Main Group ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Steatohepatitis ◽  
Complex Therapy

Objective — to establish the Antral efficacy in terms its effects on the intensity of clinical and biochemical syndromes of non‑alcoholic steatohepatitis (NASH) against the background of obesity at comorbidity with chronic obstructive pulmonary disease (COPD). Materials and methods. The examinations involved 65 NASH patients with I degree obesity and COPD 2 — 3 D. The patients were divided into two groups: 32 patients control groups received NASH therapy (Essentiale forte N (Sanofi Avensis/Nutterman and Cie GmbH) 300 mg, 2 caps., 3 times per day) for 30 days and basic COPD therapy. The second, main group consisted of 33 NASH patients with I degree obesity and COPD 2 — 3 D, who along with the basic therapy for COPD received hepatoprotector Antral (Farmak, Ukraine) 200 mg, 3 times daily for 30 days. The mean age of the patients was 56.3 ± 3.21 years. The comparison group consisted of 30 apparently healthy people (AHP). The values of 30 practically healthy individuals were used as reference. Results. According to the scale of subjective assessment of the intensity of asthenia after treatment in patients of the main group, the effectiveness of its elimination was 3.9 times higher than that of patients in the control group (relative risk 3.87; 95 % CI [1.16 — 12.91], p < 0.05). The manifestations of dyspepsia disappeared faster in the patients of the main group. The use of antral 3.7 times more influenced the manifestations of cholestasis (p < 0.05). Body mass index (BMI) > 32 kg/m2 after treatment, which included a hypocaloric diet and Antral, remained in 13 patients in the main group (39.4 %) versus 29 patients in control group (90.6 %) (p < 0.05). During one month after the treatment, markers of cytolysis remained in 9 patients in control group (28.1 %), and in 1 patient of the main group (3.0 %) (OR 9.28; 95 % CI [1.11 — 77, 52], p < 0.05). The increased activity of cholestasis markers after treatment remained only in 5 patients in the main group (15.2 %) in comparison with 22 (68.8 %) controls. In the dynamics of treatment of patients in the main group, significant increase in the protein‑synthesizing function of the liver was revealed (albumin levels increased by 30.56 % (p < 0.05) relative to the indicator in the control group). Conclusions. The use of Antral in the complex therapy of NASH of patients with the concomitant obesity and COPD was more effective than standard therapy in terms of removal of clinical NASH syndromes: asthenic‑vegetative, dyspepsia, abdominal discomfort, cholestasis, hepatomegaly, degree of liver steatosis; biochemical syndromes: cytolysis, cholestasis, mesenchymal inflammation, hepatocellular failure.  

Plasma proteolytic and fibrinolytic activity in non-alcoholic steatohepatitis, combined with chronic obstructive pulmonary disease

2014 ◽  
Vol 18 (4 (72)) ◽  
Author(s):  
T. P. Tsyntar
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Molecular Weight ◽  
High Molecular Weight ◽  
Pulmonary Disease ◽  
Fibrinolytic Activity ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Steatohepatitis ◽  
Α2 Macroglobulin ◽  
High Molecular Weight Proteins

The study involved 30 patients with NASH, 30 patients with chronic obstructive pulmonary disease and 30 patients with non-alcoholic steatohepatitis in combination with chronic obstructive pulmonary disease. A substantial enhancement of proteolysis low and high molecular weight proteins, of colagenolytic activity of plasma and nonenzymatic fibrinolysis against reduction of content of α2-macroglobulin in serum and more pronounced decrease in activity of the enzymatic fibrinolysis in this combined pathology.

scholarly journals Lipid peroxidation and oxidative modification of proteins in non-alcoholic steatohepatitis, combined with chronic obstructive pulmonary disease

2014 ◽  
Vol 18 (3 (71)) ◽  
Author(s):  
T. P. Tsyntar
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lipid Peroxidation ◽  
Pulmonary Disease ◽  
Oxidative Modification ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Oxidative Modification Of Proteins ◽  
Alcoholic Steatohepatitis

The examination of 15 NASH, 20 patients with chronic obstructive pulmonary disease and 20 patients with non-alcoholic steatohepatitis combined with chronic obstructive pulmonary disease showed a significant increase in the intensity of lipid peroxidation and oxidative modification of proteins for comorbidity.

Sign in / Sign up

Export Citation Format

Share Document